Efficacy of First-Line Immunotherapy in Metastatic Melanoma in Slovenia and Identification of Predictive Biomarkers
NCT07407166
Summary
This study evaluates the effectiveness of first-line immunotherapy in patients with metastatic melanoma treated at the Institute of Oncology Ljubljana in Slovenia. The main objectives are to assess treatment response rates, progression-free survival, and treatment safety, and to identify prognostic and predictive biomarkers associated with response to immunotherapy. Biological samples including blood, stool, and body fluids (if available) will be collected at predefined time points and analyzed for molecular tumor markers. Imaging assessments (CT or PET/CT) will be performed before treatment initiation and during follow-up to evaluate response. The study aims to improve identification of patient subgroups who benefit from immunotherapy and those who do not, supporting better personalized treatment strategies.
Eligibility
Inclusion Criteria: * Age ≥ 18 years * Metastatic (diffuse) melanoma * Planned first-line immunotherapy treatment * Signed informed consent for participation in the study Exclusion Criteria: * Age \< 18 years * Inability to provide informed consent * Any condition preventing participation or sample collection according to investigator judgment
Conditions3
Interventions1
Related trials
- A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor. — David Palma
- AI-HOPE Lung Cancer: Building a Predictive Tool for Metastatic Lung Cancer — IRCCS San Raffaele
- Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC — Peking University First Hospital
- Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer — The Second Hospital of Shandong University
- Association of Psychological Distress in Patients With Lung Cancer — Shanghai Chest Hospital
- BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases — Shandong Cancer Hospital and Institute
- CIETAI and Sequential Radiotherapy in Squamous Lung Cancer — Dong Wang
- Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer — Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07407166